Efficacy Test

All products and services are For Research Use Only and CANNOT be used in the treatment or diagnosis of disease.

Based on the outstanding expertise and rich experience, Creative Biolabs has specially developed a system approach of TCR generation and optimization for TCR development.

T cell mediated cellular immunity plays a pivotal role in tumor rejection. Through their surface T cell receptor (TCR), T cells recognize short 9-10mer peptide epitope presented by major histocompatibility complex (MHC) class I proteins on the surface of cells. Enhancing the numbers and activity of tumor-infiltrating lymphocytes (TILs), which are mostly composed of T lymphocytes, is among the early approaches that immunologists and oncologists tested to treat cancer. TCRs have been intensively studied for anti-tumor immunotherapy. The idea that targeting single epitopes derived from cancer-specific or cancer-related antigens is sufficient to treat cancer has fueled research efforts to identify suitable epitopes and has opened up many new routes for developing novel anti-cancer immunotherapy agents. Therefore, TCRs with their own advantages become significant products for cancer therapy.

Preclinical in vivo therapeutic efficacy test of TCR-T cells in animal models provides valuable information for their late clinical application. Particularly, efficacy of TCRs is a key factor for selection in clinical later stage. With years of experience in preclinical in vivo research and project management, Creative Biolabs is able to provide therapeutic efficacy test service for a proof-of-concept or therapeutic efficacy validation by utilizing appropriate animal models, designing comprehensive research practices and handling high-quality in vivo studies. We are capable of conducting many tests to evaluate the therapeutic efficacy of the CAR-T cell therapy, such as in vivo imaging, clinical observation.

Efficacy Test

Creative Biolabs has the capability to enable you to free up your time for core work and project. Our service can be designed to meet your special needs if you have any requirements. If you are interested in our service, please contact us by E-mail and our team will get back to you as soon as possible.

Reference

Demin Li, et al. Engineering chimeric human and mouse major histocompatibility complex (MHC) class I tetramers for the production of T-cell receptor (TCR) mimic antibodies. Plos One, 4 (2017): 1-16.

Key Updates

NEWSLETTER

The latest newsletter to introduce the latest breaking information, our site updates, field and other scientific news, important events, and insights from industry leaders

LEARN MORE NEWSLETTER

NEW SOLUTION

CellRapeutics™ In Vivo Cell Engineering: One-stop in vivo T/B/NK cell and macrophage engineering services covering vectors construction to function verification.

LEARN MORE SOLUTION

NOVEL TECHNOLOGY

Silence™ CAR-T Cell: A novel platform to enhance CAR-T cell immunotherapy by combining RNAi technology to suppress genes that may impede CAR functionality.

LEARN MORE NOVEL TECHNOLOGY

NEW SOLUTION

Canine CAR-T Therapy Development: From early target discovery, CAR design and construction, cell culture, and transfection, to in vitro and in vivo function validation.

LEARN MORE SOLUTION